Hamlin Capital Management LLC Sells 4,916 Shares of Johnson & Johnson $JNJ

Key Points

• Hamlin Capital Management reduced its Johnson & Johnson stake by 0.7%, selling 4,916 shares and retaining 709,904 shares valued at approximately $187.9 million. Institutional investors and hedge funds collectively own 69.55% of JNJ.
• Johnson & Johnson reported better-than-expected quarterly results, with revenue up 6.6% year over year, and maintained 2026 EPS guidance of $11.60–$11.75. The company also pays a quarterly dividend of $1.34, equivalent to a 2.1% annual yield.
• Shares recently traded at $255.15, while analysts maintain a “Moderate Buy” consensus and an average price target of $276.22. Potential catalysts include strong Innovative Medicine sales and positive oncology results, while biosimilar competition, slower MedTech growth and talc litigation remain risks.

Hamlin Capital Management LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 709,904 shares of the company's stock after selling 4,916 shares during the period. Johnson & Johnson comprises 4.6% of Hamlin Capital Management LLC's portfolio, making the stock its 6th largest holding. Hamlin Capital Management LLC's holdings in Johnson & Johnson were worth $187,940,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. YHB Investment Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.3% during the 3rd quarter. YHB Investment Advisors Inc. now owns 24,315 shares of the company's stock worth $6,437,000 after purchasing an additional 66 shares in the last quarter. Titleist Asset Management LLC grew its holdings in Johnson & Johnson by 8.4% during the 3rd quarter. Titleist Asset Management LLC now owns 7,588 shares of the company's stock valued at $2,009,000 after buying an additional 586 shares during the last quarter. Apella Capital LLC grew its holdings in Johnson & Johnson by 10.6% during the 3rd quarter. Apella Capital LLC now owns 46,998 shares of the company's stock valued at $12,147,000 after buying an additional 4,519 shares during the last quarter. Everhart Financial Group Inc. increased its position in Johnson & Johnson by 3.4% during the third quarter. Everhart Financial Group Inc. now owns 18,959 shares of the company's stock worth $5,019,000 after buying an additional 625 shares in the last quarter. Finally, Avidian Wealth Enterprises LLC raised its holdings in shares of Johnson & Johnson by 1.4% in the third quarter. Avidian Wealth Enterprises LLC now owns 38,519 shares of the company's stock worth $10,198,000 after acquiring an additional 515 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of the business's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 87,569 shares of company stock worth $23,064,544 over the last 90 days. Company insiders own 0.16% of the company's stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Investor attention is focused on JNJ’s upcoming third-quarter report. Zacks says the company has a strong history of earnings surprises and currently shows conditions that could support another beat. Its previous quarter exceeded consensus on both earnings and revenue, while full-year 2026 guidance was raised. Zacks earnings surprise article
• Positive Sentiment: Analysts remain supportive: Guggenheim reaffirmed a Buy rating with a $287 price target, and RBC Capital Markets maintained its Buy view. RBC cited accelerating Innovative Medicine sales as helping offset weakness in MedTech. RBC Capital rating article
• Positive Sentiment: JNJ reported encouraging Phase 3 results for the Tecvayli-Talvey combination in relapsed or refractory multiple myeloma, including substantial reductions in the relative risks of disease progression and death. The data could support broader use of the company’s oncology portfolio. Cancer treatment advances article
• Positive Sentiment: Two-year psoriasis data for oral ICOTYDE showed sustained skin clearance and consistent safety, strengthening the case for the medicine as a potential growth driver in difficult-to-treat psoriasis.
• Neutral Sentiment: Articles continue to highlight JNJ’s 64-year dividend-growth record and premium valuation versus Pfizer, framing the company as a lower-yield but potentially more reliable income investment. Pfizer and Johnson & Johnson dividend comparison
• Negative Sentiment: Near-term pressure may reflect risks investors are weighing before earnings, including biosimilar competition, slower MedTech growth and ongoing talc litigation. These concerns could limit valuation expansion even if pharmaceutical sales remain strong. Johnson & Johnson dividend and risk analysis

Johnson & Johnson Trading Down 1.3%

Shares of JNJ traded down $3.30 during mid-day trading on Thursday, hitting $255.15. The company had a trading volume of 2,654,376 shares, compared to its average volume of 7,953,149. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The business's 50-day simple moving average is $265.71 and its 200-day simple moving average is $248.78. The stock has a market cap of $614.88 billion, a PE ratio of 29.61, a P/E/G ratio of 2.50 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the prior year, the business posted $2.77 earnings per share. Johnson & Johnson's revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts forecast that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on JNJ shares. Wells Fargo & Company increased their price objective on Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. Johnson Rice reaffirmed a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 15th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Tuesday, September 29th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $276.22.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.